BioMarin Pharmaceutical Inc.
BMRN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.19 | 6.32 | -0.43 | 2.35 |
| FCF Yield | 3.81% | 0.35% | 0.29% | 1.15% |
| EV / EBITDA | 18.75 | 60.15 | 73.64 | 351.17 |
| Quality | ||||
| ROIC | 5.96% | 2.68% | 2.63% | -1.28% |
| Gross Margin | 79.67% | 78.01% | 76.00% | 74.52% |
| Cash Conversion Ratio | 1.34 | 0.95 | 1.24 | -4.75 |
| Growth | ||||
| Revenue 3-Year CAGR | 10.84% | 9.43% | 4.05% | 2.71% |
| Free Cash Flow Growth | 659.85% | 13.88% | -70.35% | 455.32% |
| Safety | ||||
| Net Debt / EBITDA | -0.45 | 1.11 | 1.39 | 10.59 |
| Interest Coverage | 38.23 | 10.72 | 10.08 | -5.37 |
| Efficiency | ||||
| Inventory Turnover | 0.47 | 0.48 | 0.56 | 0.61 |
| Cash Conversion Cycle | 711.80 | 638.71 | 561.30 | 521.42 |